VELPANAT combines two potent DAAs that block hepatitis C virus replication at different stages. Sofosbuvir targets NS5B polymerase, while velpatasvir inhibits NS5A protein. This dual-action therapy is included in global guidelines and offers a cure for most patients.
Recommended for:
treatment of all hepatitis C genotypes
patients with or without compensated cirrhosis
previously treated or untreated individuals
those seeking an interferon-free regimen
Indicated for the treatment of chronic hepatitis C infection in adults, regardless of viral genotype or compensated liver status.
Taken orally once daily with or without food. Standard duration is 12 weeks; dosage may be adjusted based on liver function and treatment history.
Not recommended during pregnancy, breastfeeding, or in children. Common side effects may include headache, fatigue, insomnia, and rare skin reactions or anaemia. Use under medical supervision.
